Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acict (DMXAA), a novel antivascular agent

British Journal of Cancer

Volumn 88, Issue 12, 2003, Pages 1844-1850

  Jameson, M B ^a,b,e   Thompson, P I ^a   Baguley, B C ^b   Evans, B D ^a   Harvey, V J ^a   Porter, D J ^a   McCrystal, M R ^a   Small, M ^a   Bellenger, K ^c   Gumbrell, L ^c   Halbert, G W ^d   Kestell, P ^b  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^e WAIKATO HOSPITAL   (New Zealand)

Author keywords

Antivascular; DMXAA; Phase I clinical trial

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; PLACEBO;

ADULT; AGED; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTINEOPLASTIC ACTIVITY; ANXIETY NEUROSIS; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONFUSION; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QT INTERVAL; SLURRED SPEECH; TREMOR; URINE INCONTINENCE; VISUAL DISORDER;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR SYSTEM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NERVOUS SYSTEM; TREATMENT OUTCOME; XANTHENES; XANTHONES;

EID: 0038575250     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600992     Document Type: Article

References (66)

1. Algire GH, Legallais FY, Park HD (1947) Vascular reactions of normal and malignant tissues in vivo. II. The vascular reaction of normal and neoplastic tissues of mice to a bacterial polysaccharide from Serratia marcescens (Bacillus prodigiosus) culture filtrates. J Natl Cancer Inst 8: 53-62
2. Anderson H, Jap J, Price P (2000) Measurement of tumour and normal tissue (NT) perfusion by positron emission tomography (PET) in the evaluation of antivascular therapy: results in the phase I study of combretastatin A4 phosphate (CA4P). Proc Annu Meet Am Soc Clin Oncol 19: 179
3. Aytemir K, Maarouf N, Gallagher MM, Yap YG, Waktare JE, Malik M (1999) Comparison of formulae for heart rate correction of QT interval in exercise electrocardiograms. Pacing Clin Electrophysiol 22: 1397-1401
4. Baguley BC, Zhuang L, Kestell P (1997) Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine-relation to vascular effects. Oncol Res 9: 55-60
5. Bibby MC (1991) Flavone acetic acid - an interesting novel therapeutic agent or just another disappointment. Br J Cancer 63: 3-5
6. Brown TM, Skop BP, Mareth TR (1996) Pathophysiology and management of the serotonin syndrome. Ann Pharmacother 30: 527-533
7. Cao Z, Joseph WR, Browne WL, Mountjoy KG, Palmer BD, Baguley BC, Ching LM (1999) Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 80: 716-723
8. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 25: 3666-3670
9. Chaplin DJ, Dougherty GJ (1999) Tumour vasculature as a target for cancer therapy. Br J Cancer 80(Suppl 1): 57-64
10. Ching LM, Baguley BC (1987) Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512). Eur J Cancer Clin Oncol 23: 1047-1050
11. Ching LM, Joseph WR, Crosier KE, Baguley BC (1994) Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res 54: 870-872
12. Ching LM, Wilson WR, Baguley BC (1999) Inhibition of tumour blood flow, In Methods in Molecular Medicine, Vol. 25, Drug Targeting, Francis, GE, Delgado, C (eds), Chapter 9, pp 1-26. Totowa, NJ: Humana Press Inc.
13. Cliffe S, Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR (1994) Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys 29: 373-377
14. Coley-Nauts H, Fowler GA, Bogatko FH (1953) A review of the influence of bacterial infection and bacterial products (Coley's toxins) on malignant tumours in man. Acta Med Scand 145: 5-97
15. Committee for Proprietary Medicinal Products (1997) Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products, CPMP/986/96:1-6, URL: http://www.emea.eu.int/pdfslhuman/swp/098696en.pdf
16. Council on Pharmacy and Chemistry (1934) Erysipelas and prodigiosus toxins (Coley). JAMA 103: 1067-1069
17. Davis HP, Newlands ES, Allain T, Hegde U (1988) Immune thrombocytopenia caused by flavone-8-acetic acid. Lancet 1(8582): 412
18. DeVore RF, Hellerqvist CG, Wakefield GB, Wamil BD, Thurman GB, Minton PA, Sundell HW, Yan HP, Carter CE, Wang YF, York GE, Zhang MH, Johnson DH (1997) Phase I study of the antineovascularization drug CM101. Clin Cancer Res 3: 365-372
19. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62: 3408-3416
20. Eggermont AM, ten Hagen TL (2001) Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives. Curr Oncol Rep 3: 359-367
21. Finlay GJ, Smith GP, Fray LM, Baguley BC (1988) Effect of flavone acetic acid on Lewis lung carcinoma: evidence for an indirect effect. J Natl Cancer Inst 80: 241-245
22. Galbraith SM, Lodge MA, Taylor NJ, Maxwell R, Tozer GM, Prise V, Wilson I, Sena L, Robbins A, Padhani A, Rustin G (2001) Combretastatin A4 phosphate (CA4P) reduces tumor blood flow in animals and man, demonstrated by MRI. Proc Annu Meet Am Soc Clin Oncol 20: 278a
23. Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, Thompson P, Hough D, Gumbrell L, Padhani AR (2002) Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20: 3826-3840
24. Griggs J, Hesketh R, Smith GA, Brindle KM, Metcalfe JC, Thomas GA, Williams ED (2001) Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue. Br J Cancer 84: 832-835
25. Havlin KA, Kuhn JG, Craig JB, Boldt DH, Weiss GR, Koeller J, Harman G, Schwartz R, Clark GN, Von Hoff DD (1991) Phase I clinical and pharmacokinetic trial of flavone acetic acid. J Natl Cancer Inst 83: 124-128
26. Horsman MR, Murata R, Overgaard J (1999) Improving conventional cancer therapy by targeting tumour vasculature. Br J Cancer 80: 90 (P247)
27. Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW (2001) Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor loci. Cancer Res 61: 1948-1956
28. Kaye SB, Clavel M, Dodion P, Monfardini S, ten Bokkel Huinink WW, Wagener DT, Gundersen S, Stoter G, Smith J, Renard J, Vanglabbeke M, Cavalli F (1990) Phase-II trials with flavone acetic acid (NSC-347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma. Invest New Drugs 8: S95-S99
29. Kerr DJ, Kaye SB (1989) Flavone acetic acid-preclinical and clinical activity. Eur J Cancer Clin Oncol 25: 1271-1272
30. Kerr DJ, Kaye SB, Cassidy J, Bradley C, Rankin E, Adams L, Setanoians A, Young T, Forrest G, Soukop M, Clavel M (1987) Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res 47: 6776-6781
31. Kestell P, Zhao L, Jameson MB, Stratford MR, Folkes LK, Baguley BC (2001) Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. Clin Chim Acta 314: 159-166
32. Kligfield P, Lax KG, Okin PM (1996) QT interval - heart rate relation during exercise in normal men and women: definition by linear regression analysis. J Am Coll Cardiol 28: 1547-1555
33. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR (1998) Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78: 439-445
34. Lejeune FJ, Ruegg C, Lienard D (1998) Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 10: 573-580
35. Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH (1999) Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 59: 6033-6037
36. Marmor MF, Kessler R (1999) Sildenafil (Viagra) and ophthalmology. Surv Ophthalmol 44: 153-162
37. Murata R, Overgaard J, Horsman MR (2001) Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 77: 195-204
38. O'Dwyer PJ, Shoemaker D, Zaharko S, Grieshaber C, Plowman J, Corbett T, Valeriote F, King SA, Cradock J, Hoth F, Leyland-Jones B (1987) Flavone acetic acid (LM 975, NSC 347512), a novel antitumor agent. Cancer Chemother Pharmacol 19: 6-10
39. Old LJ (1985) Tumor necrosis factor (TNF). Science 230: 630-632
40. Olver IN, Webster LK, Bishop JF, Stokes KH (1992) A phase I and pharmacokinetic study of 12-h infusion of flavone acetic acid. Cancer Chemother Pharmacol 29: 354-360
41. Otto F, Schmid P, Mackensen A, Wehr U, Seiz A, Braun M, Galanos C, Mertelsmann R, Engelhardt R (1996) Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur J Cancer 32A: 1712-1718
42. Pedley RB, Boden JA, Boden R, Boxer GM, Flynn AA, Keep PA, Begent RH (1996) Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res 56: 3293-3300
43. Pedley RB, Sharma SK, Boxer GM, Boden R, Stribbling SM, Davies L, Springer CJ, Begent RH (1999) Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res 59: 3998-4003
44. Philpott M, Baguley BC, Ching LM (1995) Induction of tumour necrosis factor-α by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 36: 143-148
45. Philpott M, Joseph WR, Crosier KE, Baguley BC, Ching LM (1997) Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Br J Cancer 76: 1586-1591
46. Pruijn FB, van Daalen M, Holford NH, Wilson WR (1997) Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 39: 541-546
47. Rewcastle GW, Atwell GJ, Li ZA, Baguley BC, Denny WA (1991) Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34: 217-222
48. Rewcastle GW, Kestell P, Baguley BC, Denny WA (1990) Light-induced breakdown of flavone acetic acid and xanthenone analogues in solution. J Natl Cancer Inst 82: 528-529
49. Rubin J, Ames M, Schutt AJ, Nichols WL, Bowie EJ, Kovach JS (1987) Flavone-8-acetic acid inhibits ristocetin-induced platelet agglutination and prolongs bleeding time. Lancet 2(8567): 1081
50. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ (1998) Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 4: 408-414
51. Rustin GJS, Galbraith SM, Taylor NJ, Maxwell R, Tozer G, Baddeley H, Wilson I, Prise V (1999) Combretastatin A4 phosphate (CA4P) selectively targets vasculature in animal and human tumors. Clin Cancer Res 5: 14
52. Rustin GJ, Bradley C, Galbraith S, Stratford M, Loadman P, Waller S, Bellenger K, Gumbrell L, Folkes L, Halbert G (2003) 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 88: 1160-1167
53. Siim BG, Lee AE, Shalal-Zwain S, Pruijin FB, McKeage MJ, Wilson WR (2003) Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 51: 43-52
54. Siim BG, Pruijn FB, Shalal-Zwain S, McKeage MJ, Wilson WR (2002) Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol
55. Smith GP, Calveley SB, Smith MJ, Baguley BC (1987) Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur J Cancer Clin Oncol 23: 1209-1211
56. Sporer KA (1995) The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf 13: 94-104
57. Spriggs DR, Yates SW (1992) Cancer chemotherapy; experiences with TNF administration in humans, In Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine, Beutler B (ed) pp 383-406. New York: Raven Press
58. Stücker O, Vicaut E, Teisseire B (1992) Specific response to 5-HT2 agonists by arterioles linked to Meth A tumors in mice. Am J Physiol 262: H704-H709
59. Van de Kar LD, Rittenhouse PA, Li Q, Levy AD (1996) Serotonergic regulation of renin and prolactin secretion. Behav Brain Res 73: 203-208
60. Wallis RM, Leishman D, Pullman L, Graepel P, Heywood R (1998) Effects of sildenafil on retinal histopathology and electroretinogram (ERG) in dogs. Ophthalmic Res 30: S68
61. Weiss RB, Green RF, Knight RD, Collins JM, Pelosi JJ, Sulkes A, Curt GA (1988) Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512). Cancer Res 48: 5878-5882
62. Wilson WR, Baguley BC (2000) Combination of the antivascular agent DMXAA with radiation and chemotherapy. Int J Radiat Oncol Biol Phys 46: 706
63. Wilson WR, Li AE, Cowan DS, Siim BG (1998) Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 42: 905-908
64. Zwi LJ, Baguley BC, Gavin JB, Holdaway KM, Wilson WR (1992) The role of immune effector cells in flavone acetic acid-induced injury to tumor cells in EMT6 spheroids. Oncol Res 4: 333-339
65. Zwi LJ, Baguley BC, Gavin JB, Wilson WR (1989) Blood flow failure as a major determinant in the antitumor action of flavone acetic acid (NSC 347512). J Natl Cancer Inst 81: 1005-1013
66. Zwi LJ, Baguley BC, Gavin JB, Wilson WR (1990) Necrosis in non-tumour tissues caused by flavone acetic acid and 5,6-dimethylxanthenone acetic acid. Br J Cancer 62: 932-934